针对中枢神经系统瘤的CAR-T疗法的进展
Delian Zhou1, Xiaojian Zhu2, Yi Xiao3
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
Biomarker research
|November 7, 2024
概括
化学抗原受体T细胞疗法对中枢神经系统瘤有希望,但克服血脑屏障和瘤微环境仍然是关键. 对EGFRvIII和CD19等目标的研究为未来战略提供了洞察力.
科学领域:
- 神经瘤学神经瘤学
- 免疫治疗是一种免疫疗法.
- 细胞疗法细胞疗法
背景情况:
- 化学抗原受体T细胞 (CAR-T) 疗法在血液性恶性瘤中取得了成功.
- 显著的挑战阻碍了CAR-T在中枢神经系统 (CNS) 瘤中的有效性,包括血脑屏障,免疫抑制微环境和抗原异质性.
研究的目的:
- 审查中枢神经系统瘤中CAR-T疗法的研究进展.
- 在临床前和临床研究中专注于针对特定抗原 (EGFRvIII,HER2,B7H3,GD2,CD19) 的CAR-T细胞.
- 为未来中枢神经系统瘤的CAR-T治疗策略提供见解.
主要方法:
- 对中枢神经系统瘤的CAR-T疗法的临床前和临床研究的文献综述.
- 针对质瘤,脑髓母细胞瘤和中枢神经系统淋巴血液构造性瘤相关的特定抗原的CAR-T细胞的分析.
- 综合当前的研究成果.
主要成果:
- 中枢神经系统瘤的CAR-T疗法研究正在推进,已确定的标显示出潜在的潜力.
- 临床前和临床研究正在探索中枢神经系统瘤中CAR-T细胞识别的各种抗原.
- 诸如血脑屏障和瘤微环境等挑战正在积极调查中.
结论:
- 卡特-T疗法具有治疗中枢神经系统瘤的潜力,但克服生物障碍至关重要.
- 需要进一步的研究和战略开发,以优化中枢神经系统恶性瘤的CAR-T疗法.
- 本综述综合了当前的知识,以指导该领域未来的治疗进展.
相关概念视频
01:27Tumor Immunotherapy
484
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
484
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K